Inclusion Criteria:  Written informed consent metastatic renal cell carcinoma (a clear-cell/ not clear-cell) Progression to previous treatment with tyrosine kinase inhibitors Patients candidates for II-line therapy with Nivolumab (or tyrosine kinase inhibitors-in the control arm)  Exclusion Criteria:  none